There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on G1 Therapeutics (GTHX) and Roche Holding AG (RHHVF) with bullish sentiments.
G1 Therapeutics (GTHX)
In a report released today, Edward White from H.C. Wainwright maintained a Buy rating on G1 Therapeutics, with a price target of $82.00. The company’s shares closed last Monday at $14.57.
According to TipRanks.com, White is a 5-star analyst with an average return of 22.8% and a 49.6% success rate. White covers the Healthcare sector, focusing on stocks such as Spectrum Pharmaceuticals, Karyopharm Therapeutics, and TRACON Pharmaceuticals.
G1 Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $56.80, which is a 278.7% upside from current levels. In a report issued on July 23, Needham also assigned a Buy rating to the stock with a $74.00 price target.
See today’s analyst top recommended stocks >>
Roche Holding AG (RHHVF)
J.P. Morgan analyst Richard Vosser maintained a Buy rating on Roche Holding AG today and set a price target of CHF400.00. The company’s shares closed last Friday at $342.50.
According to TipRanks.com, Vosser is a 4-star analyst with an average return of 11.3% and a 71.8% success rate. Vosser covers the Healthcare sector, focusing on stocks such as Molecular Partners AG, Sanofi, and UCB SA.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Roche Holding AG with a $419.02 average price target, which is a 20.0% upside from current levels. In a report issued on July 23, Goldman Sachs also maintained a Buy rating on the stock with a CHF384.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.